Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age

Prostate

Volumn 65, Issue 1, 2005, Pages 66-72

  Sävblom, Charlotte ^a,c   Malm, Johan ^a   Giwercman, Aleksander ^a   Nilsson, Jan Åke ^a   Berglund, Göran ^a   Lilja, Hans ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Univ Hospital MAS   (Sweden)

Author keywords

Age factors; PSA forms; Seminal plasma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; ARTICLE; BENIGN TUMOR; BLOOD LEVEL; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; MALIGNANT NEOPLASTIC DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE DISEASE; SEMINAL PLASMA; SPERM;

ADOLESCENT; ADULT; AGE FACTORS; ALPHA 1-ANTITRYPSIN; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; SEMEN;

EID: 24944494869     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20254     Document Type: Article

References (34)

1. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12(1):29-38.
2. Wang TJ, Rittenhouse HG, Wolfert RL, Lynne CM, Brackett NL. PSA concentrations in seminal plasma. Clin Chem 1998;44(4):895-896.
3. Becker C, Noldus J, Diamandis E, Lilja H. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci 2001;38(5):357-399.
4. Ahlgren G, Rannevik G, Lilja H. Impaired secretory function of the prostate in men with oligo-asthenozoospermia. J Androl 1995;16(6):491-498.
5. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194(3):755-763.
6. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994;220(1):45-53.
7. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76(5):1899-1903.
8. Lilja H, Lundwall A. Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein. Proc Natl Acad Sci USA 1992;89(10):4559-4563.
9. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37(9):1618-1625.
10. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51(1):222-226.
11. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273(4):289-294.
12. Tornblom M, Eriksson H, Franzen S, Gustafsson O, Lilja H, Norming U, Hugosson J. Lead time associated with screening for prostate cancer. Int J Cancer 2004;108(1):122-129.
13. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA, Lilja H. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150(1):100-105.
14. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, South wick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998;279(19):1542-1547.
15. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: Review of available data. J Urol 1996;155(1):3-9.
16. Robinson EJ, Collins AT, Robson CN, Neal DE. Effects of a new 5 alpha reductase inhibitor (epristeride) on human prostate cell cultures. Prostate 1997;32(4):259-265.
17. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-916.
18. Bjork T, Ljungberg B, Piironen T, Abrahamsson PA, Pettersson K, Cockett AT, Lilja H. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology 1998;51(1):57-62.
19. Lilja H, Haese A, Bjork T, Friedrich MG, Piironen T, Pettersson K, Huland E, Huland H. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 1999;162(6):2029-2034; discussion 2034-2025.
20. Giwercman YL, Richthoff J, Lilja H, Anderberg C, Abrahamsson PA, Giwercman A. Androgen receptor CAG repeat length correlates with semen PSA levels in adolescence. Prostate 2004;59(3):227-233.
21. Richthoff J, Rylander L, Hagmar L, Malm J, Giwercman A. Higher sperm counts in Southern Sweden compared with Denmark. Hum Reprod 2002;17(9):2468- 2473.
22. Berglund G, Eriksson KF, Israelsson B, Kjellstrom T, Lindgarde F, Mattiasson I, Nilsson JA, Stavenow L. Cardiovascular risk groups and mortality in an urban Swedish male population: The Malmo Preventive Project. J Intern Med 1996;239(6):489-497.
23. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41(8 Pt 1):1115-1120.
24. Zhang VM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem 1999;45(6 Pt 1):814-821.
25. Bjartell A, Bjork T, Matikainen MT, Abrahamsson PA, di Sant'Agnese A, Lilja H. Production of alpha-1-anti-chymotrypsin by PSA-containing cells of human prostate epithelium. Urology 1993;42(5):502-510.
26. Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, Schnorr D, Loening SA. The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: Establishment of reference ranges in a large population of healthy men. Br J Urol 1998;82(2):231-236.
27. Preston DM, Levin LI, Jacobson DJ, Jacobsen SJ, Rubertone M, Holmes E, Murphy GP, Moul JW. Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology 2000;56(5):812-816.
28. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovgren T, Lilja H. Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154(3):1090-1095.
29. Hara I, Miyake H, Hara S, Yamanaka N, Ono Y, Eto H, Takechi Y, Arakawa S, Kamidono S. Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer. BJU Int 2001;88(1):53-57.
30. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr., Bruzek DJ, Rock RC, Brendler CB, Walsh PC. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139(4):766-772.
31. Birkenmeier G, Struck F, Gebhardt R. Clearance mechanism of prostate specific antigen and its complexes with alpha2-macroglobulin and alpha1-antichymotrypsin. J Urol 1999;162(3 Pt 1):897-901.
32. Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996;48(6A Suppl):33-39.
33. Piironen T, Pettersson K, Suonpaa M, Stenman UH, Oesterling JE, Lovgren T, Lilja H. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996;48(6A Suppl):81-87.
34. Ulmert D, Becker C, Björk T, Piironen T, Hugosson J, Berglund G, Lilja H. Excellent stability of free and total PSA in edta-plasma after storage at -20°C for 25 years. Annual Meeting; Abstract: EAU CCGEN/KS/08684. 2002.